Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04450407 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3209590 in Participants With Type 1 Diabetes
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 266
- Enrollment target
NCT04450407: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT04450407 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 266 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (100% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04450407, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 266 participants
- Enrollment target
Study Summary
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 1 diabetes.
Primary Outcome
HbA1c is the glycosylated fraction of haemoglobin A. It is measured to identify average blood glucose concentration over prolonged periods of time. Least squares (LS) mean change from baseline was analysed by mixed model repeated measures (MMRM) model with treatment, country, visit, and treatment by visit interaction as fixed effects and the baseline HbA1c as a covariate.
Interventions
- DRUG LY3209590
- DRUG Insulin Degludec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 266 participants |
| Start Date | 2020-07-06 |
| Est. Completion | 2021-10-01 |
| Phase | Phase 2 |
What the finished NCT04450407 record still lists
NCT04450407 is an interventional study that assigns participants to a tested intervention. The registered 266 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (100% higher).
The record links to 0 conditions, and to 2 interventions - of which LY3209590 is the first listed.
NCT04450407 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04450407 about?
NCT04450407 is a clinical study titled "A Study of LY3209590 in Participants With Type 1 Diabetes". The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 1 diabetes.
What is the current status of trial NCT04450407?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 266 participants. The study started on 2020-07-06. Estimated completion is 2021-10-01.
What interventions are being tested in trial NCT04450407?
The interventions under investigation include: LY3209590 (DRUG), Insulin Degludec (DRUG).
Who is sponsoring clinical trial NCT04450407?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04450407's enrollment target sits among peer trials
266 209th of 2000 higher than 1,791 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05098652 · 266 participants · NA
Coaching Dementia Caregivers to Master Care-Resistant Behavior
- NCT06088277 · 266 participants · NA
Texting to Reduce Human Immunodeficiency Virus (HIV) Risk
- NCT06261814 · 266 participants · Phase 2
Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors
- NCT06312124 · 266 participants · NA
A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI